Kite, a Gilead Company, announced on April 19, 2022 that FDA has approved commercial production at the company’s new chimeric antigen receptor (CAR) T-cell therapy manufacturing facility in Frederick, Md. Kite will use the facility to product its CAR T-cell therapy used to treat blood cancer.
The new facility will add to Kite’s existing manufacturing sites in Southern California and Amsterdam, Netherlands. According to the company, the expansion will form the largest dedicated in-house cell therapy manufacturing network in the world. Kite anticipates network capacity to increase by 50%.